U.S. markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
91.46+0.20 (+0.22%)
At close: 04:00PM EDT
91.58 +0.12 (+0.14%)
After hours: 06:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Previous Close91.26
Bid91.35 x 900
Ask91.82 x 1000
Day's Range90.59 - 91.47
52 Week Range79.09 - 95.17
Avg. Volume2,590,377
Market Cap202.364B
Beta (5Y Monthly)0.51
PE Ratio (TTM)8.52
EPS (TTM)10.73
Earnings DateN/A
Forward Dividend & Yield3.33 (3.64%)
Ex-Dividend DateMar 08, 2022
1y Target Est104.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
1% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novartis AG
    Analyst Report: Novartis AGNovartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • GlobeNewswire

    FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

    68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA

  • GlobeNewswire

    Sandoz appoints new Board representative to global AMR Industry Alliance

    Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life science companies / associations in search of sustainable solutions to curb AMRSandoz, as largest global provider of generic antibiotics1, is committed to a pragmatic and balanced approach to address this growing global health threat Basel, May 27, 2020 — Sandoz is pleased to announce the appointment of

  • Insider Monkey

    Mario Gabelli is Selling These 15 Stocks in 2022

    In this article, we will look at the top 15 stocks sold by investing legend Mario Gabelli in Q1 2022. If you want to see the top 5 stocks sold by Gabelli in Q1, go to Mario Gabelli is Selling These 5 Stocks in 2022. Mario Gabelli is an Italian-American investor, financial analyst, and hedge […]